BENIGN PROSTATIC HYPERPLASIA

Open Trials

 

BPH Study Medi-Tate Protocol MT-03  

A phase II study, randomized, controlled multi-center evaluation of the safety and effectiveness of Medi-Tate temporary implantable Nitinol Device (iTIND) in subjects with symptomatic benign prostatic hyperplasia (BPH).

If you would like to learn more information about our current clinical study listed above, please contact 516-931-0041.

PHP Code Snippets Powered By : XYZScripts.com